184 related articles for article (PubMed ID: 3054627)
1. [Immunotherapy of parenchymal tumors. Recent progress and theoretical considerations].
Marincola F; Smolik L; Annoni F; Holter WD
Minerva Chir; 1988 Jul; 43(13-14):1111-31. PubMed ID: 3054627
[No Abstract] [Full Text] [Related]
2. Natural killer cells and tumor immunity: 1987.
Hiserodt JC; Herberman RB
Year Immunol; 1989; 4():201-7. PubMed ID: 2648702
[No Abstract] [Full Text] [Related]
3. Pre-clinical models for immunotherapy of melanoma.
Reisfeld RA
Prog Clin Biol Res; 1989; 288():183-93. PubMed ID: 2654950
[No Abstract] [Full Text] [Related]
4. [Induction of tumoricidal effectors from the tumor-bearer's splenocytes and the prospects of their utilization for adoptive immunotherapy].
Takagi H; Okuno K; Nakamura T; Kokudo S; Iwasa Z; Yasutomi M
Nihon Gan Chiryo Gakkai Shi; 1986 May; 21(4):721-7. PubMed ID: 3489799
[No Abstract] [Full Text] [Related]
5. [A new approach to immunotherapy of cancer based on autologous T-lymphocytes].
Dosne Pasqualini C; Laguens RP
Medicina (B Aires); 1987; 47(3):307-12. PubMed ID: 3326997
[No Abstract] [Full Text] [Related]
6. [Immunotherapy of malignant diseases].
Dorval T; Michon J; Tartour E; Fridman WH
Bull Cancer; 1995; 82 Suppl 2():127s-138s. PubMed ID: 7542946
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
8. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
Reisfeld RA; Gillies SD
J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
[No Abstract] [Full Text] [Related]
9. [Effects of interleukin-2 and lymphokine-activated killer cells on cell cultures and on transplanted tumors (nude mouse) of human pancreatic carcinomas].
Kühl JS; Klapdor R; Bahlo M; Arps H; Dietel M; Mohr M
Beitr Infusionther Klin Ernahr; 1987; 18():261-5. PubMed ID: 3501948
[No Abstract] [Full Text] [Related]
10. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
11. [The interleukin-2-LAK system in cancerology].
Fridman WH
Pathol Biol (Paris); 1989 Feb; 37(2):94-5. PubMed ID: 2652081
[No Abstract] [Full Text] [Related]
12. [Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism].
Kosugi A; Fujiwara H; Hamaoka T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1527-35. PubMed ID: 6236750
[TBL] [Abstract][Full Text] [Related]
13. Biological response modifiers: the new immunotherapy.
Foon KA
Cancer Res; 1989 Apr; 49(7):1621-39. PubMed ID: 2466558
[No Abstract] [Full Text] [Related]
14. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
Hooijberg E; Sein JJ; van den Berk PC; Hart AA; van der Valk MA; Kast WM; Melief CJ; Hekman A
Cancer Res; 1995 Jun; 55(12):2627-34. PubMed ID: 7540106
[TBL] [Abstract][Full Text] [Related]
15. [Use of monoclonal antibodies in the immunotherapy of neoplasms].
Robak T
Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121
[No Abstract] [Full Text] [Related]
16. [Using LAK cells in the adoptive immunotherapy in cancers].
Urushizaki I
Rinsho Ketsueki; 1987 Oct; 28(10):1897-8. PubMed ID: 3502569
[No Abstract] [Full Text] [Related]
17. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
18. Cocktails of human anti-cancer antibodies show a synergistic effect in nude mouse tumor xenografts.
Glassy MC; McKnight ME; Kotlan B; Glassy EF; Koda K
Hum Antibodies; 2007; 16(3-4):87-98. PubMed ID: 18334744
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
20. [Biological immunomodulators in the treatment of cancer].
Bello C; Richard C; Hermosa V; Iriondo A; Muruzábal MJ; Pérez Encinas M; Zubizarreta A
Sangre (Barc); 1988 Apr; 33(2):132-43. PubMed ID: 2456623
[No Abstract] [Full Text] [Related]
[Next] [New Search]
